Web Analytics

3 Latest Announced Rounds

  • $3,700,000
    Seed
    Technology, Information and Internet
    Apr 3rd, 2025
  • $3,700,000
    Seed
    Technology, Information and Internet
    Apr 3rd, 2025
  • $2,198,930
    Pre-Seed
    Software Development
    Apr 3rd, 2025
$1,096.86M Raised in 38 Funding Rounds in the past 7 Days - View All

Funding Round Profile

DermBiont, Inc.

start up
United States - Boston, Massachusetts
  • 25/10/2023
  • Series B
  • $35,200,000

DermBiont’s mission is to become the world’s leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root causes of skin diseases through the development of targeted small molecule therapeutics with well-defined mechanisms of action and biotherapeutics that repair an imbalance of the microbiome. The company’s targeted topical therapeutics pipeline includes SM-020 for the treatment of seborrheic keratosis, SM-030 for the treatment of hyperpigmentation disorders of the skin, and DBI-001 & DBI-002 for the treatment of atopic dermatitis, tinea pedis, and onychomycosis. For more information, please visit www.dermbiont.com.


Related People

Karl BeutnerCo Founder

Karl Beutner United States - Fairfield, California

N/A